Marinus Pharmaceuticals, Inc. (MRNS)
NASDAQ: MRNS · Real-Time Price · USD
1.600
+0.090 (5.96%)
Sep 19, 2024, 4:00 PM EDT - Market closed
Marinus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 30.26 | 30.99 | 25.48 | 15.35 | 1.72 | - | Upgrade
|
| Revenue Growth (YoY) | 16.56% | 21.63% | 66.03% | 793.19% | - | - | Upgrade
|
| Cost of Revenue | 97.43 | 101.32 | 81.42 | 75 | 50.51 | 42.27 | Upgrade
|
| Gross Profit | -67.16 | -70.33 | -55.94 | -59.65 | -48.79 | -42.27 | Upgrade
|
| Selling, General & Admin | 65.56 | 61.15 | 56.85 | 37.28 | 19.15 | 12.16 | Upgrade
|
| Research & Development | 0.47 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 66.03 | 61.15 | 56.85 | 37.28 | 19.15 | 12.16 | Upgrade
|
| Operating Income | -133.19 | -131.49 | -112.79 | -96.93 | -67.94 | -54.42 | Upgrade
|
| Interest Expense | -17.5 | -16.9 | -10.67 | -2.58 | - | - | Upgrade
|
| Interest & Investment Income | 6.21 | 8.11 | 2.35 | 0.08 | 0.5 | 0.35 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.25 | 1.39 | -1.87 | 0.9 | -0.04 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -143.23 | -138.88 | -122.97 | -98.53 | -67.48 | -54.12 | Upgrade
|
| Gain (Loss) on Sale of Assets | -4 | -4 | 107.38 | - | - | - | Upgrade
|
| Asset Writedown | -0.06 | -0.06 | -0.83 | -0.24 | - | - | Upgrade
|
| Pretax Income | -149.24 | -142.94 | -16.43 | -98.78 | -67.48 | -54.12 | Upgrade
|
| Income Tax Expense | - | -1.54 | 3.39 | - | - | - | Upgrade
|
| Net Income | -149.24 | -141.41 | -19.82 | -98.78 | -67.48 | -54.12 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 8.88 | - | Upgrade
|
| Net Income to Common | -149.24 | -141.41 | -19.82 | -98.78 | -76.36 | -54.12 | Upgrade
|
| Shares Outstanding (Basic) | 56 | 54 | 39 | 37 | 27 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 56 | 54 | 39 | 37 | 27 | 14 | Upgrade
|
| Shares Change (YoY) | 20.37% | 37.56% | 6.47% | 34.57% | 100.10% | 33.30% | Upgrade
|
| EPS (Basic) | -2.66 | -2.63 | -0.51 | -2.69 | -2.80 | -3.97 | Upgrade
|
| EPS (Diluted) | -2.66 | -2.63 | -0.51 | -2.69 | -2.80 | -3.97 | Upgrade
|
| Free Cash Flow | -120.62 | -118.12 | -114.66 | -58.37 | -60.91 | -49.02 | Upgrade
|
| Free Cash Flow Per Share | -2.15 | -2.20 | -2.93 | -1.59 | -2.23 | -3.60 | Upgrade
|
| Gross Margin | -221.93% | -226.96% | -219.57% | - | - | - | Upgrade
|
| Operating Margin | -440.11% | -424.30% | -442.69% | -631.68% | -3954.42% | - | Upgrade
|
| Profit Margin | -493.14% | -456.31% | -77.78% | -643.70% | -4444.41% | - | Upgrade
|
| Free Cash Flow Margin | -398.59% | -381.17% | -450.04% | -380.36% | -3545.52% | - | Upgrade
|
| EBITDA | -128.66 | -126.13 | -111.41 | -96.58 | -67.6 | -54.14 | Upgrade
|
| D&A For EBITDA | 4.53 | 5.36 | 1.37 | 0.36 | 0.33 | 0.28 | Upgrade
|
| EBIT | -133.19 | -131.49 | -112.79 | -96.93 | -67.94 | -54.42 | Upgrade
|
| Revenue as Reported | 30.26 | 30.99 | 25.48 | 15.35 | 1.72 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.